| 26013 |
Budesonide suppository |
Budenofalk® |
Budesonide suppository (Budenofalk®) is indicated for short-term treatment of mild-to-moderate acute ulcerative colitis limited to the rectum (ulcerative proctitis) in adult patients. |
Rapid Review Complete |
13th April 2026 |
 |
| 26007 |
Decitabine/cedazuridine |
Inaqovi® |
Decitabine/cedazuridine (Inaqovi®) is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. |
Rapid Review Complete |
8th April 2026 |
|
| 25010 |
Durvalumab |
Imfinzi® |
Durvalumab (Imfinzi®) is indicated as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy. |
NCPE Assessment Process Complete |
2nd April 2026 |
|
| 24005 |
Fezolinetant |
Veoza™ |
Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. |
NCPE assessment ongoing |
7th April 2026 |
|
| 25037 |
Glofitamab |
Columvi® |
Glofitamab in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT). |
Awaiting response from Applicant |
1st April 2026 |
|
| 24052 |
Lecanemab |
Leqembi® |
Lecanemab (Leqembi®) is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology. |
Awaiting response from Applicant |
10th April 2026 |
|
| 25013 |
Ravulizumab |
Ultomiris® |
Ravulizumab (Ultomiris®) is indicated for the treatment of adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin 4 antibody positive. |
Full HTA submission received from Applicant |
10th April 2026 |
|
| 24018 |
Relugolix with estradiol and norethisterone acetate |
Ryeqo® |
Relugolix with estradiol and norethisterone acetate (Ryeqo®) is Indicated in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. |
Awaiting response from Applicant |
8th April 2026 |
|
| 24039 |
Sodium Zirconium Cyclosilicate |
Lokelma® |
Sodium Zirconium Cyclosilicate is indicated for the treatment of hyperkalaemia in adult patients. |
NCPE assessment ongoing |
15th April 2026 |
|
| 26009 |
Tislelizumab |
Tevimbra® |
Tislelizumab (Tevimbra®) in combination with pemetrexed and platinum containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells with no EGFR or ALK positive mutations and who have: • locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or • metastatic NSCLC. |
Rapid Review Complete |
10th April 2026 |
|
| 26010 |
Tislelizumab |
Tevimbra® |
Tislelizumab (Tevimbra®) in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of adult patients with squamous non-small cell lung cancer (NSCLC) who have: • locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or • metastatic NSCLC. |
Rapid Review Complete |
10th April 2026 |
|
| __ |
__ |
__ |
__ |
__ |
13th April 2026 |
|
